度普利尤单抗治疗老年特应性皮炎:多中心真实世界研究
这项多中心回顾性真实世界研究纳入276例≥65岁重度特应性皮炎(AD)患者,占重度AD患者的11.37%。度普利尤单抗治疗16周后所有评分显著下降,疗效与18-64岁组无显著差异,仅6.52%因无效停药,22.51%报告不良事件,以结膜炎和潮红最常见。
要点
- 度普利尤单抗治疗老年重度AD 16周可显著改善EASI、P-NRS、S-NRS和DLQI评分。
- 老年患者疗效与18-64岁患者相比无统计学显著差异。
- 不良事件报告率22.51%,结膜炎和潮红最常见,仅0.36%因不良事件停药。
核心结论
- 度普利尤单抗治疗16周可显著改善老年重度AD,安全性良好,可考虑作为老年AD的有效安全治疗。
研究设计与样本
- 多中心回顾性观察性真实世界研究,纳入≥65岁重度AD(EASI≥24)患者,度普利尤单抗按标签剂量治疗16周。
主要发现
- 共纳入276例患者,占所有重度AD患者的11.37%。
- 屈侧湿疹是最常见临床表型,其次为结节性痒疹,63/276(22.82%)存在一种以上表型共存。
- 253例(91.67%)有16周治疗数据,所有评分均显著下降。
- 老年患者疗效与18-64岁组相比无统计学显著差异。
关键数值与推荐
- 重度AD定义为EASI≥24。
- 疗效评估指标包括客观EASI和主观P-NRS、S-NRS、DLQI,比较基线与16周。
- 停药原因:无效18/276(6.52%),不良事件1/276(0.36%)。
临床怎么用
- 老年重度AD患者可考虑使用度普利尤单抗,16周疗程可显著改善客观与主观评分。
- 治疗中需关注结膜炎和潮红等不良事件,但因此停药率低。
局限性
- 回顾性观察性研究设计。
- 仅报告16周短期数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment of moderate-to-severe atopic dermatitis (AD) in the elderly may be challenging, due to side-effects of traditional anti-inflammatory drugs and to comorbidities often found in this age group. Furthermore, efficacy and safety of innovative drugs such as dupilumab are not yet well known. OBJECTIVES: A multicentre retrospective, observational, real-life study on the efficacy and safety of dupilumab was conducted in a group of patients aged ≥65 years and affected by severe AD. Their main clinical features were also examined. METHODS: Data of elderly patients with severe (EASI ≥24) AD treated with dupilumab at label dosage for 16 weeks were retrospectively collected. Treatment outcome was assessed by comparing objective (EASI) and subjective (P-NRS, S-NRS and DLQI) scores at baseline and after 16 weeks of treatment. RESULTS: Two hundred and seventy-six patients were enrolled in the study. They represented 11.37% of all patients with severe AD. Flexural eczema was the most frequent clinical phenotype, followed by prurigo nodularis. The coexistence of more than one phenotype was found in 63/276 (22.82%) subjects. Data on the 16-week treatment with dupilumab were available for 253 (91.67%) patients. Efficacy of dupilumab was demonstrated by a significant reduction of all the scores. No statistically significant difference regarding efficacy was found in elderly patients when compared to the group of our AD patients aged 18-64 years, treated with dupilumab over the same period. Furthermore, only 18 (6.52%) patients discontinued the drug due to inefficacy. Sixty-one (22.51%) patients reported adverse events, conjunctivitis and flushing being the most frequent. One (0.36%) patient only discontinued dupilumab due to an adverse event. CONCLUSIONS: Therapy with dupilumab led to a significant improvement of AD over a 16-week treatment period, with a good safety profile. Therefore, dupilumab could be considered as an efficacious and safe treatment for AD also in the elderly.
引用
- Patruno C, Napolitano M, Argenziano G, et al. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study. J Eur Acad Dermatol Venereol. 2021. PMID: 33332697. doi:10.1111/jdv.17094
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。